Diabetic Retinopathy Market Research
What is Diabetic Retinopathy?
Retinopathy (DR) is an eye condition that can cause vision loss and blindness in individuals with diabetes. Having too much sugar in the blood can damage the retina by blocking tiny blood vessels causing them to leak fluid or bleed. First, DR may cause no symptoms or only mild vision problems. However, over time it can lead to blindness. The condition can develop in anyone who has type 1 or type 2 diabetes. The longer diabetes remains uncontrolled, the more likely one is to develop DR. For individuals with diabetes, it is important to get a comprehensive dilated eye exam at least once a year.
Spherix Global Insights – Ophthalmology – Diabetic Retinopathy (DR)
Spherix’s Ophthalmology team covers the Diabetic Retinopathy (DR) market in our Special Topix™ and Patient Chart Dynamix™ services. Spherix’s has the following studies publishing this year covering DR:
- Special Topix™: Diabetic Retinopathy (US)
- Patient Chart Dynamix™: Treatment Switching in Diabetic Retinopathy (US)
- Patient Chart Dynamix™: New Starts in Diabetic Retinopathy (US)
- Launch Dynamix™: Eylea HD in Diabetic Retinopathy (US)
Spherix’s Special Topix™ service is an independent service that includes access to a report or series of reports based on current events or topics of interest in specialty markets covered by Spherix.
Spherix’s Patient Chart Dynamix™ service includes patient-level data detailing clinical and non-clinical patient demographics, along with rationale for treatment choices. It reveals real patient management patterns through rigorous analysis of large-scale patient chart audits.
Spherix’s Launch Dynamix™ service consists of two parts: monthly KPI tracking and quarterly deep dives. Monthly KPIs provide benchmarking of newly launched products for the first eighteen months of commercial availability, and quarterly deep dive reports includes promotional activity, barriers to uptake, and patient types gravitating to the launch brand.
Follow Spherix Ophthalmology on Social Media
Follow us for ophthalmology industry news, insights & analysis:
Twitter: https://twitter.com/SpherixOphtha
LinkedIn: https://www.linkedin.com/company/spherix-global-insights/
For Guests & Current Clients
For more details on Spherix’s primary market research reports and interactive dashboard offerings, visit or register here:
Blaine Cloud
Franchise Leader, Ophthalmology
Email: [email protected]